Pro-drug of GS-441524 and medical application thereof

By designing the prodrug derivatives of GS-441524, the inconvenience and resistance of existing nucleoside anti-coronavirus drugs during drug use are solved, and the stability and efficacy of the gastrointestinal tract and lung tissues are achieved. improves the effect of antiviral treatment.

CN119019400AActive Publication Date: 2024-11-26CHINA PHARM UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310581042.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26
Estimated Expiration
2043-05-23

AI Technical Summary

Technical Problem

Existing nucleoside anti-coronavirus drugs such as remdesivir and monupivir have inconvenience and potential drug resistance problems during the drug use, and their metabolite GS-441524 is insufficient in vivo distribution and stability, which affects the impact of The sustainability of the efficacy of the medicine.

Method used

A class of prodrug derivatives of GS-441524 are designed, with a compound represented by formula (I), which has good stability in the gastrointestinal tract and excellent levels of triphosphate active metabolites in plasma and lung tissues. Synthesis method is prepared as a pharmaceutical composition for anti-coronavirus treatment as described in the Examples.

Benefits of technology

The ideal pharmacokinetic properties in vitro and in vitro are achieved, the half-life of GS-441524 in plasma is extended, the level of active triphosphate metabolites in lung tissues is improved, and the sustainability of antiviral efficacy is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019400A_ABST
    Figure CN119019400A_ABST
Patent Text Reader

Abstract

The invention discloses a prodrug of GS-441524 and a medical application of the prodrug of GS-441524. The invention provides a novel GS-441524 prodrug derivative. The structural formula of the novel GS-441524 prodrug derivative is shown as a formula (I). Compared with the prior art, the GS-441524 prodrug derivative disclosed by the invention has ideal in-vivo and in-vitro pharmacokinetic properties; the stability in gastrointestinal tracts is good, and the exposure amount of GS-441524 in plasma and lung tissues is ideal; the excellent triphosphate active metabolite level is realized in lung tissues. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and relates to a prodrug of GS-441524 and its medical use, and specifically relates to a class of prodrugs of GS-441524. The present invention also relates to the medical use of such compounds as anti-coronavirus drugs. Background Art

[0002] There is an urgent need to develop new broad-spectrum antiviral drugs for coronaviruses (such as SARS-CoV-1, MERS-CoV, and SARS-CoV-2). Nucleoside drugs are a hot spot in the research and development of broad-spectrum anti-coronavirus drugs. This type of drug is converted into nucleoside triphosphates in the body and acts on the relatively conservative target of coronaviruses, RNA-dependent RNA polymerase (RdRp), producing a direct antiviral effect by blocking the replication of genetic material. The RdRp between the four different species of coronaviruses has the same catalytic mechanism, and the active site contains similar key conserved amino acids. For this reason, nucleoside drugs have the potential to be developed into broad-spectrum anti-coronavirus drugs with a high barrier to drug resistance; using this type of drug as a core component of antiviral treatment is the need for future drug development and clinical treatment.

[0003] Among the global nucleoside anti-coronavirus drugs, remdesivir is the first drug approved for the treatment of lung lesions caused by COVID-19 infection, and has clear broad-spectrum anti-coronavirus activity; however, it requires daily intravenous injection of 100 mg, and the course of treatment is generally 5 to 10 days, which greatly reduces medication compliance. Monuprivir was approved for marketing in the UK on November 4, 2021, and is the first oral drug for the treatment of COVID-19. The drug has a large dosage and needs to be taken twice a day, 800 mg each time. In addition, whether the drug has mutagenic or reproductive toxicity still needs to be further determined. Azvudine has dual activity against HIV and coronavirus, and is currently approved for marketing in my country. In addition, AT-527 is in Phase 2 clinical trials, but the latest research data show that the molecule failed to meet the expected primary endpoint.

[0004] Remdesivir is mostly converted into the nucleoside GS-441524 in the plasma. After the metabolite is distributed in the lung tissue, it is converted into the triphosphate active metabolite GS-441524-TP to exert its efficacy. It is worth noting that a number of reports have confirmed that direct oral administration of GS-441524 can also achieve ideal antiviral effects. The domestic drug VV116 under development is a prodrug of a deuterated derivative of GS-441524, while ATV006 is a 5'-hydroxyisobutyrylated prodrug of GS-441524. Both have broad-spectrum in vitro anti-coronavirus activity. It can be seen that the design and development of new prodrugs is the key to giving the nucleoside GS-441524 new drugability and therapeutic effects. Summary of the invention

[0005] In view of the problems existing in the prior art, the first object of the present invention is to provide a novel prodrug derivative of GS-441524.

[0006] The second object of the present invention is to provide medical uses of the aforementioned GS-441524 prodrug derivatives.

[0007] In order to achieve the above object, the technical solution adopted by the present invention to solve the technical problem is:

[0008] In the first aspect, the present invention provides a novel prodrug derivative of GS-441524, the structural formula of which is shown in formula (I):

[0009]

[0010] Among them, R 1 Selected from: H, C 1-6 Alkyl, benzyl or n is selected from: 0, 1, 2 or 3; m is selected from: 0, 1, 2 or 3; W is selected from: R 2 Selected from: H, C 2-7 Acyl or C 3-6 Cycloalkylformyl; R 3 Select from: H or C 1-3 Alkyl; R 4 Select from: H or C 1-3 alkyl.

[0011] Furthermore,

[0012] R 1 Selected from: H, C 1-6 Alkyl, benzyl, n is selected from: 0 or 1; m is selected from: 0 or 1; W is selected from: R 2 is selected from: H, acetyl, propionyl, n-butyryl, isobutyryl, cyclopropylcarbonyl or cyclobutylcarbonyl; R 3 Selected from: H or methyl; R 4 Selected from: H or methyl.

[0013] Furthermore,

[0014] R 1 Selected from: H, benzyl, n is selected from: 0 or 1; m is selected from: 0 or 1; W is selected from: R 2 is selected from: H, isobutyryl, or cyclobutylcarbonyl; R 3 Selected from: H or methyl; R 4 Selected from: H or methyl.

[0015] Furthermore,

[0016] The compound of formula (I) is any one of compounds 1 to 24 having the following structures, or a combination thereof:

[0017]

[0018]

[0019] Most preferably, the compound of formula (I) is selected from the group consisting of I-4, I-5, I-7, I-8, I-10, I-11, I-12, I-13, I-15, I-16, I-17, I-19, I-21, I-23, and I-24.

[0020] In a second aspect, the present invention also protects a pharmaceutical composition comprising the GS-441524 derivative described above or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, stereoisomer or solvate thereof, and a pharmaceutically acceptable carrier.

[0021] In the third aspect, the present invention also protects the use of the GS-441524 derivatives described above or their pharmaceutically acceptable salts, tautomers, mesomers, racemates, stereoisomers or solvates or the compositions described above in the preparation of anti-coronavirus drugs.

[0022] The coronavirus is selected from: severe acute respiratory syndrome coronavirus SARS-CoV (Severe acute respiratory syndrome coronavirus, SARS-CoV), 2019 novel coronavirus (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (Human coronavirus OC43), human coronavirus 229E (Human coronavirus 229E), human coronavirus NL63 (Human coronavirus NL63), human coronavirus HKUl (Human coronavirus HKUl).

[0023] definition

[0024] Unless otherwise specified, the following terms used in this application have the following meanings. A particular term should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to the common meaning in the art. When a trade name appears in this article, it is intended to refer to the corresponding commodity or its active ingredient.

[0025] In this article, C 1-3, means that the moiety has 1-3 carbon atoms in the given range. Specifically, it means that the group can have 1 carbon atom, 2 carbon atoms or 3 carbon atoms.

[0026] The term "alkyl" refers to a group of the formula C n H 2n+1 The alkyl group may be straight chain or branched. For example, the term "C 1-3 The term "alkyl" refers to an alkyl group containing 1 to 3 carbon atoms (eg, methyl, ethyl, n-propyl, isopropyl).

[0027] The term "pharmaceutically acceptable" refers to those compounds, materials, compositions and / or dosage forms which, within the scope of sound medical judgment, are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0028] As the pharmaceutically acceptable salt, for example, metal salts, ammonium salts, salts with organic bases, salts with inorganic acids, salts with organic acids, salts with basic or acidic amino acids and the like can be mentioned.

[0029] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or their salts and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.

[0030] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0031] The present application also includes isotope-labeled compounds of the present application that are identical to those described herein, but one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number commonly found in nature. Examples of isotopes that can be incorporated into compounds of the present application include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 13N, 15N, 15O, 17O, 18O, 31P, 32P, 35S, 18F, 123I, 125I, and 36Cl, etc.

[0032] The pharmaceutical composition of the present application can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols, etc.

[0033] Typical routes of administration of the compounds of the present application or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0034] The pharmaceutical composition of the present application can be manufactured by methods well known in the art, such as conventional mixing methods, dissolution methods, granulation methods, sugar-coated pill making methods, grinding methods, emulsification methods, freeze-drying methods, etc.

[0035] In some embodiments, the pharmaceutical composition is in oral form. For oral administration, the pharmaceutical composition can be prepared by mixing the active compound with pharmaceutically acceptable excipients well known in the art. These excipients enable the compounds of the present application to be formulated into tablets, pills, lozenges, dragees, capsules, liquids, gels, slurries, suspensions, etc., for oral administration to patients.

[0036] Solid oral compositions can be prepared by conventional mixing, filling or tableting methods. For example, they can be obtained by mixing the active compound with a solid excipient, optionally grinding the resulting mixture, adding other suitable excipients if necessary, and then processing the mixture into particles to obtain a tablet or dragee core. Suitable excipients include, but are not limited to, adhesives, diluents, disintegrants, lubricants, glidants, sweeteners or flavoring agents, etc.

[0037] The pharmaceutical composition may also be suitable for parenteral administration, such as sterile solutions, suspensions or lyophilized products in appropriate unit dosage forms.

[0038] The compounds of the present application can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitution methods well known to those skilled in the art. Preferred embodiments include but are not limited to the examples of the present application.

[0039] The chemical reactions of the specific embodiments of the present application are carried out in a suitable solvent, which must be suitable for the chemical changes of the present application and the reagents and materials required. In order to obtain the compounds of the present application, it is sometimes necessary for those skilled in the art to modify or select the synthesis steps or reaction processes based on the existing embodiments.

[0040] Beneficial Effects

[0041] Compared with the prior art, the GS-441524 prodrug derivative of the present invention has ideal in vitro and in vivo pharmacokinetic properties; good stability in the gastrointestinal tract, ideal exposure of GS-441524 in plasma and lung tissue; and excellent levels of triphosphate active metabolites in lung tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 is the H NMR spectrum of compound 1-4.

[0043] Figure 2 This is the H NMR spectrum of compound I-12.

[0044] Figure 3 The results of in vitro metabolism study of compound I-4.

[0045] Figure 4 The results of in vitro metabolism study of compound I-12.

[0046] Figure 5 The results of in vivo metabolism studies of compounds I-4 and I-5.

[0047] Figure 6 is the exposure of the active metabolite RTP of the representative compound in the lung. DETAILED DESCRIPTION

[0048] The present invention is specifically described below by way of examples. In the present invention, the following examples are intended to better illustrate the present invention and are not intended to limit the scope of the present invention. Various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.

[0049] Example 1 Synthesis of Compound I-1

[0050]

[0051] Synthesis of compound II. GS-441524 (4370 mg, 15 mmol) was placed in a two-necked bottle, protected by argon, and 70 mL of acetone was added to dissolve it, and then 2,2-dimethoxypropane (9.1 mL, 72 mmol) was added and stirred at room temperature. Concentrated sulfuric acid (1083 μL, 19.5 mmol) was slowly added dropwise, and the reaction was allowed to react at room temperature for 30 min, then the temperature was raised to 45 °C and the reaction was continued for 30 min. After the reaction was complete as monitored by TLC, the reaction solution was cooled to room temperature, solid sodium bicarbonate (2.9 g) and water (2.9 mL) were added and stirred for 15 min. The reaction solution was concentrated in vacuo, and the crude product was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=15:1) to obtain a white foamy intermediate (4.9 g, 98.6%). The intermediate (2900 mg, 8.76 mmol) was placed in a two-necked bottle, protected by argon, 6 mL of acetonitrile was added to dissolve, N,N-dimethylformamide acetal (1272 μL, 10.51 mmol) was added dropwise, and the reaction was carried out at room temperature for 2 h. After the reaction was complete as monitored by TLC, the reaction solution was concentrated in vacuo, and the crude product was slurried with anhydrous ether, filtered, and dried to obtain a white solid II (3.09 g, 93.6%). 1 H NMR(300MHz,Chloroform-d)δ8.90(s,1H),8.03(s,1H),7.13(d,J=4.6Hz,1H),6.95(d,J=4.6Hz,1H),5.45(d,J=6.6Hz,1H),5.26(dd, J=6.6,2.4Hz,1H),4.80–4.55(m,2H),4.02(d,J=12.3Hz,1H),3.86(t,J=11.9Hz,1H),3.28(d,J=5.9Hz,6H),1.83(s,3H),1.41(s,3H).

[0052] Synthesis of compound III. Compound II (386 mg, 1 mmol), benzyl succinate (312 mg, 1.5 mmol), EDCI (288 mg, 1.5 mmol) and DMAP (183 mg, 1.5 mmol) were placed in a sealed tube, 5 mL of dichloromethane was added, and the mixture was heated at 60°C for 3 h. After the reaction was complete as monitored by TLC, the reaction solution was cooled to room temperature, a saturated aqueous sodium carbonate solution was added to the reaction solution, the reaction solution was extracted with DCM, washed with a saturated aqueous sodium carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=30:1) to obtain an oily substance III (547 mg, 95%). 1H NMR(300MHz,Chloroform-d)δ8.85(s,1H),8.11(s,1H),7.45–7.27(m,5H),7.03(dd,J =4.6,1.2Hz,1H),6.90(dd,J=4.6,1.3Hz,1H),5.53(d,J=6.7Hz,1H),5.13(s,2H),4.93 (dd,J=6.9,4.2Hz,1H),4.67–4.56(m,1H),4.44(dd,J=12.0,4.3Hz,1H),4.31(dd,J=11 .8,5.6Hz,1H),3.24(d,J=8.2Hz,6H),2.67(d,J=4.0Hz,4H),1.78(s,3H),1.43(s,3H).

[0053] Synthesis of compound I-1. Compound III (576 mg, 1 mmol) was placed in a single-mouth bottle, 6.2 mL of anhydrous ethanol was added to dissolve, and glacial acetic acid (1145 μL, 20 mmol) was added, and heated at 50 ° C overnight. After the reaction was complete as monitored by TLC, the reaction solution was concentrated in vacuo, 2.5 mL of 90% trifluoroacetic acid was added, and the reaction was allowed to react at room temperature for 2 h. After the reaction was complete as monitored by TLC, a saturated aqueous sodium bicarbonate solution was added to the reaction bottle to adjust the pH to 8, the reaction solution was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=15:1) and slurried with n-hexane to obtain a white solid compound I-1 (400 mg, 83.1%). 1 H NMR(300MHz,Methanol-d4)δ7.88(s,1H),7.32(s,5H),6.90(s,2H),5.10(s,2H ),4.88(d,J=5.4Hz,1H),4.49–4.24(m,3H),4.15(t,J=5.7Hz,1H),2.65(s,4H). 13 C NMR(126MHz,Methanol-d4)δ172.39,172.31,155.87,136.05,128.13,127.78,127.7 4,124.19,116.61,116.28,110.89,82.09,80.15,74.16,70.68,66.11,28.59,28.53.

[0054] Example 2 Synthesis of Compound I-2

[0055]

[0056] Referring to the method in Example 1, compound II (386 mg, 1 mmol) was used as the raw material, monobenzyl succinate was replaced with monoisopropyl succinate, and a white solid I-2 (104 mg, two-step yield 74%) was finally obtained after two steps of reaction. 1 H NMR (300MHz, Methanol-d4) δ7.88(s,1H),6.91(s,2H),4.96(q,J=6.3Hz,1H),4.90(d,J=5.4Hz ,1H),4.51–4.26(m,3H),4.16(t,J=5.6Hz,1H),2.57–2.62(m,4H),1.20(dd,J=6.3,2.2Hz,6H). 13 C NMR (126MHz, Methanol-d4) δ172.40,172.18,155.87,146.94,124.22,116.60,116. 27,110.90,101.17,82.10,80.18,74.16,70.69,68.08,63.30,28.91,28.55,20.62.

[0057] Example 3 Synthesis of Compound I-3

[0058]

[0059] Referring to the method in Example 1, compound II (386 mg, 1 mmol) was used as the raw material, monobenzyl succinate was replaced with monomethyl succinate, and a white solid I-3 (166 mg, two-step yield 76%) was finally obtained after two steps of reaction. 1 H NMR (300MHz, Methanol-d4) δ7.88 (s, 1H), 6.91 (s, 2H), 4.89 (d, J = 5.3Hz, 1H), 4.52–4.27(m,3H),4.16(t,J=5.6Hz,1H),3.66(s,3H),2.61(d,J=2.8Hz,4H). 13 C NMR(126MHz,Methanol-d4)δ173.12,172.31,155.89,146.94,124.22,116.5 9,116.25,110.84,82.07,80.15,74.17,70.70,63.24,50.90,28.49,28.27.

[0060] Example 4 Synthesis of Compound I-4

[0061]

[0062] Compound II (348 mg, 0.9 mmol), succinic anhydride (50 mg, 0.5 mmol), and DMAP (91 mg, 0.75 mmol) were placed in a two-necked bottle, protected by argon, 5 mL of DCM was added to dissolve, triethylamine (140 uL, 1.0 mmol) was added dropwise, and the mixture was reacted at room temperature for 2 h. The reaction was complete as monitored by TLC, and the reaction solution was transferred to a sealed tube, EDCI (144 mg, 0.75 mmol) was added, and the mixture was reacted at 60 °C for 2 h. The reaction was complete as monitored by TLC, and the reaction solution was extracted with DCM, washed with saturated sodium carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=30:1) to obtain a white solid (337 mg, 79%), and a portion of it (285 mg, 0.33 mmol) was taken for the next step of deprotection: 2 mL of anhydrous ethanol was added to a single-mouth bottle to dissolve, and then glacial acetic acid (377 μL, 20 mmol) was added, and heated at 50°C overnight. After the reaction was complete as monitored by TLC, the reaction solution was concentrated in vacuo, 2 mL of 90% trifluoroacetic acid was added, and the reaction was allowed to react at room temperature for 2 h. After the reaction was completed as monitored by TLC, saturated aqueous sodium bicarbonate solution was added to the reaction bottle to adjust the pH to 8. The reaction solution was extracted with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was purified by silica gel column chromatography (DCM / MeOH=10:1) and slurried with n-hexane to obtain a white solid I-4 (180 mg, 82.2%). 1 H NMR (300MHz, Methanol-d4) δ7.87(s,2H),6.90(s,4H),4.91(d,J=5.3Hz,2H),4.51–4.25(m,6H),4.18(t,J=5.5Hz,2H),2.60(s,4H). 13 C NMR (126MHz, Methanol-d4) δ172.24,155.85,146.93,124.12,116.59,116.32,110.88,101.23,82.18,80.04,74.17,70.69,63.19,28.42.

[0063] Example 5 Synthesis of Compound I-5

[0064]

[0065] Compound I-1 (165 mg, 0.34 mmol) and palladium carbon (33 mg, 20% w / w) were placed in a two-necked bottle, replaced with hydrogen three times, and 3 mL of anhydrous ethanol was added to dissolve and reacted at room temperature for 2 h. After the reaction was complete as monitored by TLC, the mixture was filtered through diatomaceous earth, and the filtrate was concentrated in vacuo. The obtained product was slurried with n-hexane to obtain a white solid I-5 (130 mg, 97%).1 H NMR (300MHz, Methanol-d4) δ7.88 (s, 1H), 6.91 (s, 2H), 4.90 (s, 1H), 4.52–4.25 (m, 3H), 4.17 (t, J = 5.6Hz, 1H), 2.59 (s, 4H). 13 CNMR(126MHz,Methanol-d4)δ174.87,172.59,155.87,146.88,124.25,116.5 7,116.25,110.84,101.19,82.11,80.07,74.20,70.67,63.10,28.70,28.58.

[0066] Example 6 Synthesis of Compound I-6

[0067]

[0068] Referring to the method in Example 1, compound II was used as the raw material, monobenzyl succinate was replaced with monobenzyl glutarate, and a white solid I-6 was finally obtained after three steps of reaction. 1 H NMR(300MHz,Methanol-d4)δ7.87(s,1H),7.46–7.19(m,5H),6.89(s,2H),5.09(s,2 H),4.51–4.25(m,3H),4.15(t,J=5.7Hz,1H),2.49–2.27(m,4H),1.98–1.80(p,2H). 13 C NMR(126MHz,Methanol-d4)δ173.07,172.90,155.86,146.95,136.20,128.13,127.76,127.74,1 16.59,116.27,110.80,101.18,82.07,80.13,74.25,70.73,65.87,63.01,32.62,32.50,19.84.

[0069] Example 7 Synthesis of Compound I-7

[0070]

[0071] Referring to the method of Example 4, compound II was used as the raw material, succinic anhydride was replaced with glutaric anhydride, and finally a white solid I-7 was obtained. 1H NMR (300MHz, Methanol-d4) δ7.87(s,2H),6.88(s,4H),4.88(s,2H),4.50–4.25(m,6H),4.17(t,J=5.7Hz,2H),2.49–2.21(m,4H),1.87–1.79(m,2H). 13 C NMR (126MHz, Methanol-d4) δ172.87,155.83,146.93,124.18,116.57,116.32,110.83,101.24,82.20,80.00,70.78,62.97,32.45,19.69.

[0072] Example 8 Synthesis of Compound I-8

[0073]

[0074] Referring to the method of Example 5, compound I-6 was used as raw material to prepare white solid I-8. 1 H NMR (300MHz, Methanol-d4) δ7.88(s,1H),6.91(s,2H),4.88(s,1H),4.54–4.27(m,3H),4.22–4.12(m,1H),2.49–2.26(m,4H),1.87(m,2H). 13 CNMR(126MHz,Methanol-d4)δ175.68,173.02,155.86,146.89,124.27,116. 56,110.79,101.22,82.10,80.04,74.26,70.75,62.95,32.73,32.63,19.95.

[0075] Example 9 Synthesis of Compound I-9

[0076]

[0077] Referring to the method in Example 1, compound II was used as the raw material, monobenzyl succinate was replaced with (S)-4-(benzyloxy)-2-methyl-4-oxobutanoic acid, and finally a white solid I-9 was obtained. 1H NMR(300MHz, Methanol-d4)δ7.87(s,1H),7.32(s,5H),6.90(d,J=1.2Hz,2H),5.18–5.00(m,2H),4.89(s,1H),4.46–4.25(m,3H ),4.14(t,J=5.5Hz,1H),3.06–2.82(m,1H),2.71(dd,J=16.7,8.6Hz,1H),2.53(dd,J=16.7,5.5Hz,1H),1.18(d,J=7.1Hz,3H). 13 C NMR (126MHz, Methanol-d4) δ175.16,171.82,155.87,146.96,136.03,128.17,127.87,127.85,124. 21,116.63,116.33,110.98,101.21,82.05,80.14,74.19,70.68,66.12,63.38,37.07,35.83,15.90.

[0078] Example 10 Synthesis of Compound I-10

[0079]

[0080] Compound II (155 mg, 0.4 mmol), (S)-2-methylsuccinic acid (26.4 mg, 0.2 mmol), EDCI (115 mg, 0.6 mmol) and DMAP (25 mg, 0.2 mmol) were placed in a sealed tube, 3 mL of dichloromethane was added, and the mixture was heated at 60°C for 3 h. After the reaction was complete as monitored by TLC, the reaction solution was cooled to room temperature, a saturated aqueous sodium carbonate solution was added to the reaction solution, the reaction solution was extracted with DCM, washed with a saturated aqueous sodium carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=30:1) to obtain a white foamy solid (165 mg, 95%). 1H NMR(300MHz,Chloroform-d)δ8.89(s,2H),8.10(s,2H),7.02(d,J=4.5Hz,2H) ,6.90(d,J=4.5Hz,2H),5.52(d,J=6.7Hz,2H),5.01–4.85(m,2H),4.70–4.51( m,2H),4.49–4.24(m,4H),3.26(d,J=3.8Hz,12H),3.02–2.86(m,1H),2.83–2. 65(m,1H),2.54–2.37(m,1H),1.78(s,6H),1.42(s,6H),1.21(d,J=7.1Hz,3H).

[0081] Referring to the synthesis method of Example 4, the above product was deprotected to obtain white solid I-10 (302 mg, 78.2%). 1 HNMR(300MHz, Methanol-d4)δ7.87(s,2H),6.89(s,4H),4.90(d,J=5.3Hz,2H),4.49–4.26(m,6H),4.16(q,J=5.4,4 .7Hz,2H),2.86(q,J=7.2Hz,1H),2.65(dd,J=16.8,8.0Hz,1H),2.46(dd,J=16.6,6.0Hz,1H),1.15(d,J=7.0Hz,3H). 13 C NMR(126MHz,Methanol-d4)δ175.08,171.68,155.83,146.95,124.17,124.15,116.59,116.37,116.35,110.99,11 0.98,101.27,82.08,82.06,80.10,80.09,74.21,70.77,70.71,63.34,63.28,47.86,47.52,36.85,35.68,15.81.

[0082] Example 11 Synthesis of Compound I-11

[0083]

[0084] Referring to the method of Example 5, compound I-9 was used as raw material to prepare white solid I-11. 1H NMR (300MHz, Methanol-d4) δ7.89 (d, J = 7.0Hz, 1H), 6.92 (q, J = 4.6Hz, 2H), 4.93 (s, 1H), 4.52–4.31 (m, 3H), 4.28–4. 10(m,1H),2.89(q,J=7.2Hz,1H),2.65(dd,J=16.7,8.1Hz,1H),2.42(dd,J=16.7,6.1Hz,1H),1.18(d,J=7.1Hz,3H). 13 C NMR(126MHz,Methanol-d4)δ175.53,174.46,155.87,146.88,124.27,116.59,1 16.30,110.95,101.28,82.08,80.06,74.23,70.66,63.20,37.28,35.91,15.90.

[0085] Example 12 Synthesis of Compound I-12

[0086]

[0087] Referring to the method in Example 1, compound II was used as the raw material, monobenzyl succinate was replaced with 4-(benzyloxy)-2,2-dimethyl-4-oxobutanoic acid, and finally a white solid I-12 was obtained. 1 H NMR(300MHz, Methanol-d4)δ7.87(s,1H),7.31(s,5H),6.97–6.80(m,2H),5.04(s,2H),4.88(d,J=5.4Hz,1H), 4.37(dd,J=6.1,3.8Hz,1H),4.30(d,J=4.2Hz,2H),4.13(t,J=5.7Hz,1H),2.65(s,2H),1.22(d,J=5.3Hz,6H). 13 C NMR (126MHz, Methanol-d4) δ176.74,171.29,155.89,146.99,135.98,128.16,127.97,127.86,124. 25,116.65,116.34,110.95,82.20,80.01,74.21,70.69,66.02,63.53,43.70,40.44,24.48,24.36.

[0088] Example 13 Synthesis of Compound I-13

[0089]

[0090] Referring to the method of Example 5, the dibasic acid was replaced with 2,2-dimethyl-4-oxobutanoic acid to finally obtain white solid I-13. 1 H NMR (300MHz, Methanol-d4) δ7.87 (s, 2H), 6.89 (d, J = 1.5Hz, 4H), 4.90 (s, 2H), 4. 46–4.23(m,6H),4.22–4.08(m,2H),2.57(d,J=3.5Hz,2H),1.19(d,J=4.4Hz,6H). 13 CNMR(126MHz,Methanol-d4)δ176.70,171.16,147.00,146.95,124.22,124.15,116.61,116.39,116.36,11 0.97,110.95,82.25,82.10,79.92,74.26,74.19,70.87,70.73,63.51,63.23,43.40,40.38,24.35,24.27.

[0091] Example 14 Synthesis of Compound I-14

[0092]

[0093] Referring to the method of Example 5, compound I-12 was used as raw material to prepare white solid I-14. 1 H NMR(300MHz,Methanol-d4)δ7.88(s,1H),6.92(s,2H),4.88(s,1H),4.49–4.24 (m,3H),4.15(t,J=5.6Hz,1H),2.45(d,J=3.1Hz,2H),2.37(s,2H),1.10(s,6H). 13 C NMR(126MHz,Methanol-d4)δ177.20,173.97,155.87,146.90,124.33,116.6 0,116.35,110.91,101.31,82.31,79.84,74.31,70.66,63.31,44.09,40.28.

[0094] Example 15 Synthesis of Compound I-15

[0095]

[0096] Referring to the method in Example 1, compound II was used as the raw material, monobenzyl succinate was replaced with 5-(benzyloxy)-3,3-dimethyl-5-oxopentanoic acid, and finally a white solid I-15 was obtained. 1 H NMR (300MHz, Methanol-d4) δ7.87(s,1H),7.33(s,5H),6.90(s,2H),5.07(s,2H),4.88(d,J=5.1H z,1H),4.44–4.25(m,3H),4.13(t,J=5.5Hz,1H),2.44(s,2H),2.41(d,J=3.6Hz,2H),1.06(s,6H). 13 C NMR(126MHz,Methanol-d4)δ171.80,171.60,155.88,146.94,136.22,128.12,127.95,127.77,124.24, 116.59,116.28,110.85,101.17,82.06,80.06,74.22,70.81,65.64,62.86,44.51,44.40,32.20,26.67.

[0097] Example 16 Synthesis of Compound I-16

[0098]

[0099] Referring to the method of Example 4, compound II was used as the raw material, succinic anhydride was replaced with 3,3-dimethylglutaric anhydride, and finally a white solid I-16 was obtained. 1 H NMR (300MHz, Methanol-d4) δ7.87 (s, 2H), 6.89 (d, J = 3.6Hz, 4H), 4.89 (s, 2H), 4.46–4.22(m,6H),4.15(t,J=3.9,2.4Hz,2H),2.46–2.26(m,4H),1.02(s,6H). 13 C NMR (126MHz, Methanol-d4) δ171.64,155.84,146.95,124.23,116.58,110.92,101.31,82.13,74.29,70.87,62.85,44.41,32.15,26.64.

[0100] Example 17 Synthesis of Compound I-17

[0101]

[0102] Referring to the method of Example 5, compound I-15 was used as raw material to prepare white solid I-17. 1 H NMR(300MHz,Methanol-d4)δ7.88(s,1H),6.92(s,2H),4.88(s,1H),4.49–4.24 (m,3H),4.15(t,J=5.6Hz,1H),2.45(d,J=3.1Hz,2H),2.37(s,2H),1.10(s,6H). 13 C NMR (126MHz, Methanol-d4) δ174.45,171.82,155.87,124.29,116.31,110.89,101.29,82.09,80.00,74.27,70.84,62.83,44.85,31.91,26.61.

[0103] Example 18 Synthesis of Compound I-18

[0104]

[0105] Referring to the method in Example 1, compound II was used as the raw material, and monobenzyl succinate was replaced with (E)-4-methoxy-4-oxo-2-enoic acid to obtain white solid I-18 (412 mg, 83%). 1 H NMR (300MHz, Methanol-d4) δ7.87 (s, 1H), 6.89 (s, 2H), 6.78 (s, 2H), 4.94 (d, J = 5.3 Hz,1H),4.69–4.55(m,1H),4.49–4.38(m,2H),4.24(t,J=5.6Hz,1H),3.82(s,3H). 13 C NMR(126MHz,Methanol-d4)δ165.26,164.44,155.87,146.98,133.24,132.66,12 4.09,116.65,116.23,110.89,101.18,82.01,80.25,74.10,70.69,63.55,51.47.

[0106] Example 19 Synthesis of Compound I-19

[0107]

[0108] Compound I-4 (664 mg, 1 mmol), isobutyric acid (528 mg, 6 mmol), EDCI (1150 mg, 6 mmol) and DMAP (244 mg, 2 mmol) were placed in a sealed tube, 20 mL of acetonitrile was added, and the mixture was heated at 60°C for 12 h. After the reaction was complete as monitored by TLC, the reaction solution was cooled to room temperature, a saturated aqueous sodium carbonate solution was added to the reaction solution, the reaction solution was extracted with DCM, washed with a saturated aqueous sodium carbonate solution and saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo. The crude product was chromatographed on a silica gel column (DCM / MeOH=30:1) to obtain a waxy product I-19 (490 mg, 52%). HRMS (ESI) for C 44 H 53 N 10 O 14 [M+H] + calcd945.3737, found 945.3749.

[0109] Example 20 Synthesis of Compound I-20

[0110]

[0111] Referring to the method of Example 19, compound I-1 was used as a raw material to obtain white solid I-20. HRMS (ESI) for C 31 H 36 N5O9[M+H] + calcd 622.2508,found 622.2499.

[0112] Example 21 Synthesis of Compound I-21

[0113]

[0114] Referring to the method of Example 5, compound I-20 was used as a raw material to obtain white solid I-21. HRMS (ESI) for C 24 H 28 N5O9[MH] - calcd 530.1893,found 530.1901.

[0115] Example 22 Synthesis of Compound I-22

[0116]

[0117] Referring to the method of Example 19, compound I-7 was used as a raw material to obtain white solid I-22. HRMS (ESI) for C 37 H 39 N 10 O14 [M+H] + calcd 847.2642,found 847.2649.

[0118] Example 23 Synthesis of Compound I-23

[0119]

[0120] Referring to the method of Example 19, compound I-6 was used as a raw material to obtain white solid I-23. HRMS (ESI) for C 34 H 38 N5O9[M+H] + calcd 660.2664, found 660.2673.

[0121] Example 24 Synthesis of Compound I-24

[0122]

[0123] Referring to the method of Example 5, compound I-23 was used as a raw material to obtain white solid I-24. HRMS (ESI) for C 27 H 30 N5O9[MH] - calcd 568.2049,found 568.2057.

[0124] In vitro stability of the compound of Example 25

[0125] 1. HPLC method

[0126] The chromatographic column used was Waters XSelect HSS T3 (4.6×150 mm, 3.5 μm), the mobile phase consisted of 0.1% formic acid water (v / v) (A) and acetonitrile (B), the column temperature was 40° C., the flow rate was 1 mL / min, and the injection volume was 5 μL. The UV detection wavelength was 254 nm.

[0127] Gradient elution program ① is: 0-2.8 min, 1% B; 2.8-3 min, 1-12% B; 3-5.5 min, 12% B; 5.5-5.7 min, 12-25% B; 5.7-8 min, 25% B; 8-8.2 min, 25-46% B; 8.2-13 min, 46% B; 13-13.1 min, 46-1% B; 13.1-16 min, 1% B.

[0128] Gradient elution program ② is: 0-2.8 min, 1% B; 2.8-3 min, 1-12% B; 3-5.5 min, 12% B; 5.5-5.7 min, 12-20% B; 5.7-8 min, 20% B; 8-8.2 min, 20-46% B; 8.2-13 min, 46% B; 13-13.1 min, 46-1% B; 13.1-16 min, 1% B.

[0129] Gradient elution program ③ is: 0-2.8 min, 1% B; 2.8-3 min, 1-18% B; 3-8 min, 18% B; 8-8.2 min, 18-46% B; 8.2-13 min, 46% B; 13-13.1 min, 46-1% B; 13.1-16 min, 1% B.

[0130] Gradient elution program ④ is: 0-2.8 min, 1% B; 2.8-3 min, 1-13% B; 3-6 min, 13% B; 6-6.5 min, 13-32% B; 6.5-8.5 min, 32% B; 8.5-9 min, 32-52% B; 9-13 min, 52% B; 13-13.1 min, 52-1% B; 13.1-16 min, 1% B.

[0131] Gradient elution program ⑤ is: 0-2.8 min, 1% B; 2.8-3 min, 1-12% B; 3-5.5 min, 12% B; 5.5-5.7 min, 12-30% B; 5.7-8 min, 30% B; 8-8.2 min, 30-37% B; 8.2-14 min, 37% B; 14-14.1 min, 37-1% B; 14.1-17 min, 1% B.

[0132] Gradient elution program ⑥ is: 0-2.8 min, 1% B; 2.8-3 min, 1-12% B; 3-5.5 min, 12% B; 5.5-5.7 min, 12-21% B; 5.7-8 min, 21% B; 8-8.2 min, 21-40% B; 8.2-14 min, 40% B; 14-14.1 min, 40-1% B; 14.1-17 min, 1% B.

[0133] 2. Matrix Preparation

[0134] Preparation of liver S9 and intestinal S9 of SD rats: Rats were fasted for 12 hours in advance, and the liver and small intestine were immediately removed after being killed by cervical dislocation, washed with 4°C PBS buffer, chopped and homogenized in PBS buffer. After homogenization, centrifuged at 9000g for 20 minutes (4°C), the upper fat layer and the lower sediment were discarded, the intermediate liquid was collected and divided into 50mL centrifuge tubes, and stored at -40°C for later use. The protein concentration was determined using the BCA method.

[0135] Preparation of SD rat plasma: Blood was collected from the venous plexus of the retina of the rat. The whole blood was pre-treated with EDTA 2K + Store in the treated centrifuge tube, centrifuge at 8000rpm for 5min, take the upper light yellow clear liquid as plasma, and store at -40℃ until use.

[0136] 3. Sample processing

[0137] Accurately weigh 10 mg of each compound and internal standard (SOF), add 1 mL of DMSO to the internal standard, shake thoroughly and dissolve into a colorless clear liquid, with a final concentration of 10 mg / mL; add appropriate amount of DMSO to the remaining compounds, shake thoroughly and dissolve into a clear liquid, with a final concentration of 50 mM. The obtained stock solution is stored at 4°C for future use and frozen at -40°C.

[0138] 1485 μL of blank plasma was accurately transferred and preheated in a 37°C water bath for 5 min. Then, 15 μL of each reserve solution was added to start the hydrolysis reaction (the final drug concentration in the system was 0.5 mM, and DMSO did not exceed 1%). After incubation in a 37°C water bath for 5 min, 10 min, 15 min, 30 min, 1 h, 2 h, and 4 h, 50 μL of the incubated sample was added to 100 μL of glacial acetonitrile (containing internal standard SOF 100 μg / mL) to terminate the reaction, vortexed for 5 min, centrifuged at 12000 rpm for 5 min twice, and 75 μL of the supernatant was taken for sample analysis to determine the drug concentration. The experiment was repeated 3 times in parallel (n=3).

[0139] After the protein concentration of each tissue was determined by the BCA method, S9 was uniformly diluted to 0.2 mg / mL with ice PBS for use (operation on ice). 1485 μL of the diluted SD rat liver and intestine S9 was accurately pipetted and preheated in a 37°C water bath for 5 minutes, followed by adding 15 μL of each reserve solution under 2.2 to start the hydrolysis reaction (the final drug concentration in the system is 0.5 mM, and DMSO does not exceed 1%). After incubation in a 37°C water bath for 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours, 50 μL of the incubated sample was added to 100 μL of ice acetonitrile (containing internal standard SOF 100 μg / mL) to terminate the reaction, vortexed for 5 minutes, centrifuged at 12000 rpm for 5 minutes twice, and 75 μL of the supernatant was taken for sample analysis to determine the drug concentration. The experiment was repeated 3 times in parallel (n=3).

[0140] IV. Experimental Results

[0141] Using the established HPLC analysis method, a standard curve was drawn to detect the residual concentration of the drug in the incubation system and a concentration-time curve was drawn. Nonlinear regression was performed with time (X, min) as the abscissa and the residual concentration of the obtained compound (Y, μM) as the ordinate. The exponential decay equation was obtained by integrating both sides to calculate the half-life. The results are shown in the following table:

[0142] Table 1. In vitro stability of compounds

[0143]

[0144]

[0145] Among them, the structure of ATV006 is:

[0146]

[0147] The experimental results show that compared with the isobutyl ester prodrug compound ATV006, the multiple compounds involved in the present invention (I-4, I-5, I-7, I-8, I-10 to I-17, I-19, I-21, I-23, I-24) have better stability in the intestine S9, which suggests that the compounds can effectively avoid first-pass elimination in the intestine. In liver S9 and plasma, multiple compounds (I-4, I-12, I-19, I-23, I-24) show an ideal degradation trend and can metabolize the active molecule GS-441524 (attached Figure 3 and 4 ), which suggests that these compounds can better achieve metabolic activation in the liver and plasma, which is beneficial to the exposure of GS-441524 in plasma and lung tissue.

[0148] Example 20 In vivo pharmacokinetic study

[0149] 1. Instruments and Materials

[0150] Ultra-high performance liquid chromatography-tandem quadrupole mass spectrometry (including two Shimadzu LC-20A infusion pumps, SIL-20AC autosampler, CTO-20A column oven, CBM-20A system controller; AB SCIEX mass spectrometry system API4000, electrospray ionization source ESI); Analyst 1.5.1 workstation; XSelect HSS T3 chromatographic column (4.6×150 mm, 3.5 μm; Waters, Canada); AUW 120D electronic analytical balance (Shimadzu, Japan); Eppendorf AG 22331 centrifuge (Hamburg, Germany); XW-80A vortex mixer (Shanghai Medical University Instrument Factory); ThermoMixer C oscillator (Eppendorf, Hamburg, Germany); Sorfwall high-speed refrigerated centrifuge (Thermo Fishers Scientific, USA); -80°C ultra-low temperature freezer (Thermo Fishers Scientific, USA); Milli-Q Gradient A10 ultrapure water machine (Millipore, Amsterdam, The Netherlands), etc. The purity of the compound and internal standard sofosbuvir was > 98%.

[0151] 2. Animal Experiments

[0152] Thirty SD rats were divided into five groups, with six rats in each group. The gavage (ig) dose of each administration group was 0.15 mmol / kg. The pharmacokinetic characteristics of each prodrug and its metabolite in SD rats after a single administration of each drug were investigated. Each drug was accurately weighed and prepared into a solution or suspension with 5% DMSO-95% 0.5% CMC-Na solution (v / v) for gavage (ig) administration.

[0153] Each group of SD rats fasted for 12 hours before administration, but not water. 0.3 mL of blood was collected from the eye socket before administration and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36 and 48 hours after administration, respectively. After centrifugation at 8000 rpm for 5 minutes in a 1.5 mL centrifuge tube treated with EDTA-2Na anticoagulant in advance, 100 μL of upper plasma was taken, 5 μL of citric acid (2M) and 5 μL of NaF (0.2M) were added to inhibit enzyme activity, vortexed thoroughly, and frozen at -80°C until injection analysis. Among them, the plasma sample pretreatment was as follows: SD rat plasma samples were thawed at room temperature, 50 μL of plasma samples were taken, and ice acetonitrile containing 100 ng / mL internal standard (SOF) was added to precipitate protein, vortexed for 5 minutes, centrifuged at 18000 rpm (4°C) for 5 minutes twice, and the upper supernatant was taken for LC-MS / MS injection analysis.

[0154] After blood collection, the rats were bled from the femoral artery, and the thoracic and abdominal cavities were opened after being killed by cervical vertebrae dislocation. The liver, kidney and lung tissues were collected (all operations were performed on ice), and the blood on all tissues was washed with ice PBS. After the remaining water was absorbed by filter paper, all tissues were quickly frozen in liquid nitrogen. The frozen rat tissues were stored at a ratio of tissue mass / homogenate volume (g / v) = 1 / 5, and all tissue homogenate samples were frozen in a -80°C refrigerator for analysis.

[0155] LC-MS / MS Experiment

[0156] 1. Liquid phase conditions

[0157] The chromatographic column used was an XSelect HSS T3 column (4.6×150 mm, 3.5 μm), the mobile phase consisted of an aqueous solution containing 0.1% formic acid (phase A) and an acetonitrile solution containing 0.1% formic acid, the column temperature was 40°C, the flow rate was 0.6 mL / min, and the gradient elution program was: 0-2 min, 1% B; 2-10 min, 1-90% B; 10-11 min, 90% B; 11-12 min, 90-1% B; 12-15 min, 1% B. The injection volume was 5 μL.

[0158] 2. Mass spectrometry conditions

[0159] The mass spectrometer selected the electrospray ion source (ESI), and the ion source parameters were set as follows: Curtain Gas / CUR 35Arb; Collision Gas / CAD, N2 10Arb; IonSpray Voltage / IS 5500V; Ion Source Heating Temperature (Temperature / TEM) 550℃, Auxiliary Gas 1 (Ion Source Gas1) 60Arb; Auxiliary Gas 2 (IonSource Gas2) 65Arb. Each analyte was scanned in the positive ion mode; the sample was detected in the multiple reaction monitoring (MRM) mode. The Q0 entrance potential (Entrance potential / EP) was set to 10V, and the Q2 exit potential (Collision Cell Exit Potential / CXP) was set to 15V.

[0160] 3. Data Analysis

[0161] The drug concentration in the plasma of SD rats after administration was fitted with Phoenix WinNolin 6.4 non-compartmental model (NACand Toolbox, NAC) to calculate the pharmacokinetic parameters.

[0162] IV. Experimental Results

[0163] The plasma and tissue pharmacokinetic behavior and pharmacokinetic parameters of each prodrug and metabolite GS-441524 in SD rats are shown in the attached Figure 5 and 6 .

[0164] Attached Figure 5 In this study, we selected GS-5245 (ATV006) as the control compound, and administered compounds I-4, I-5 and GS-5245 (0.15 mmol / kg) orally, and compared the pharmacokinetic properties of the common metabolite GS-441524 of the three prodrugs. The experimental results show that the AUC of GS-441524 in compound I-4 (Cpd 4) is 0.5 times that of GS-5245. max is 0.45 times that of GS-5245, while T max It is 4.2 times that of GS-5245. 1 / 2 It is 3 times longer than that of GS-5245.

[0165] The results of the study suggest that the new prodrug designed in the present invention is beneficial for prolonging the half-life of the metabolite GS-441524 in plasma; 90 Calculated at 1 μM (refer to existing literature), compound I-4 has a more ideal effective concentration duration, which is about 11 hours; while the effective duration of GS-5245 is 8 hours.

[0166] In addition, we evaluated the tissue distribution characteristics of different prodrugs (0.15mmol / kg) after oral administration. First, we quantified the key metabolite GS-441524 in the lungs and plasma at 4 hours and calculated the lung-to-blood ratio. The results are shown in the table below. The experimental results show that the compound of the present invention can be metabolized to GS-441524 in the body and has an unexpectedly high lung-to-blood ratio; this suggests that the prodrug of the present invention can be beneficial to the exposure of GS-441524 in the lungs and the exertion of its efficacy.

[0167] Table GS-441524 exposure ratio in lung tissue and plasma after administration of different compounds

[0168]

[0169]

[0170] The triphosphate metabolite RTP is the key metabolite that ultimately exerts antiviral efficacy. Subsequently, we investigated the exposure of the compound to RTP in lung tissue at 4 hours. The experimental results showed that (Appendix Figure 6), after GS-441524 was transformed into a prodrug, the content of RTP in the lung increased significantly. The prodrug compound of the present invention has excellent pharmacokinetic properties and can effectively increase the content of RTP in the lung, which also suggests that compounds I-4, I-12 and I-24 all have ideal antiviral activity.

[0171] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. It should be pointed out that for ordinary technicians in this technical field, improvements or changes can be made based on the above description, and these improvements and changes should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A prodrug derivative of GS-441524, whose structural formula is shown in formula (I): in, R 1 Selected from: H, C 1-6 Alkyl, benzyl or n is selected from: 0, 1, 2 or 3; m is selected from: 0, 1, 2 or 3; W is selected from: R 2 Selected from: H, C 2-7 Acyl or C 3-6 Cycloalkylformyl; R 3 Select from: H or C 1-3 Alkyl; R 4 Select from: H or C 1-3 alkyl.

2. The prodrug derivative according to claim 1, characterized in that R 1 Selected from: H, C 1-6 Alkyl, benzyl, n is selected from: 0 or 1; m is selected from: 0 or 1; W is selected from: R 2 is selected from: H, acetyl, propionyl, n-butyryl, isobutyryl, cyclopropylcarbonyl or cyclobutylcarbonyl; R 3 Selected from: H or methyl; R 4 Selected from: H or methyl.

3. The prodrug derivative according to claim 2, characterized in that R 1 Selected from: H, benzyl, n is selected from: 0 or 1; m is selected from: 0 or 1; W is selected from: R 2 is selected from: H, isobutyryl, or cyclobutylcarbonyl; R 3 Selected from: H or methyl; R 4 Selected from: H or methyl.

4. The prodrug derivative according to claim 3, characterized in that The compound of formula (I) is any one of compounds 1 to 24 having the following structures, or a combination thereof:

5. A pharmaceutical composition, characterized in that The GS-441524 derivative or a pharmaceutically acceptable salt, tautomer, mesoform, racemate, stereoisomer or solvate thereof according to any one of claims 1 to 4.

6. The pharmaceutical composition according to claim 5, characterized in that The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

7. Use of the prodrug derivative of GS-441524 according to claim 1 or its pharmaceutically acceptable salt, tautomer, mesomer, racemate, stereoisomer or solvate in the preparation of a drug for anti-coronavirus infection.

8. The use according to claim 7, characterized in that The coronavirus is selected from: severe acute respiratory syndrome coronavirus SARS-CoV (Severe acute respiratory syndrome coronavirus, SARS-CoV), 2019 novel coronavirus (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (Human coronavirus OC43), human coronavirus 229E (Human coronavirus 229E), human coronavirus NL63 (Human coronavirus NL63), human coronavirus HKUl (Human coronavirus HKUl).

9. Use of the pharmaceutical composition according to claim 5 or 6 in the preparation of a medicament for resisting coronavirus infection.

10. The use according to claim 9, characterized in that The coronavirus is selected from: severe acute respiratory syndrome coronavirus SARS-CoV (Severe acute respiratory syndrome coronavirus, SARS-CoV), 2019 novel coronavirus (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), human coronavirus OC43 (Human coronavirus OC43), human coronavirus 229E (Human coronavirus 229E), human coronavirus NL63 (Human coronavirus NL63), human coronavirus HKUl (Human coronavirus HKUl).

Citation Information

Patent Citations

  • Nucleoside prodrug and application thereof

    CN113999237A

  • Compound or composition for treating or preventing feline infectious peritonitis

    CN114621229A

  • Prodrugs of 1'-substituted carba-nucleoside analogues for antiviral treatment

    US20220227776A1

  • Orally-bioavailable nucleoside analogs

    WO2022265964A1